BMS Wins Broader Use, New Adjuvant Market For Yervoy
This article was originally published in Scrip
Executive Summary
Bristol Myers Squibb Co. on Oct. 28 won the FDA's approval to expand the use of Yervoy (ipilimumab) as an adjuvant treatment for patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1mm who have undergone complete resection including total lymphadenectomy.